Developer docs
API playgroundTry for free, no card

Search company profiles

cbdMD

Full company profile

uuid0000ydb

Namestring
cbdMD
Legal namestring
cbdMD, Inc.
Websiteurl
cbdmd.com
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCharlotte, United States
HQ citystring
Charlotte
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CBD wellness products, hemp-derived supplements, THC beverages, pet CBD products, broad spectrum CBD
Industry5 codes
PRIMARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAD
Hemp-Derived Delta-8/Delta-9/THC-A Specialty Retail (Where Legal)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAF
CBD/Hemp Pet Products Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAB
CBD/Hemp Topicals & Beauty Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRAOAIAG
Hemp & CBD Product Wholesale Distribution
Consumer Products & Retail/Wholesale, Distribution & Category Management/Alcohol, Tobacco & Cannabis Wholesale Distribution
NAICS code3 codes
  • Food (Health) Supplement Retailers456191
  • Tobacco, Electronic Cigarette, and Other Smoking Supplies Retailers459991
  • Pharmacies and Drug Retailers456110
SIC code2 codes
  • Retail-Drug Stores And Proprietary Stores5912
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Hemp-Derived CBD Wellness Products
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Direct-to-Consumer E-commerce
TypeSubscription Recurring
Description

Online sales through cbdmd.com website representing the majority of revenue (77% of FY2025 net sales at $14.7 million). Customers purchase various CBD products including gummies, tinctures, capsules, and topicals with Subscribe & Save subscription options offering 25% recurring discounts.

investing.com
2Wholesale Distribution
TypeTransaction Fee
Description

Wholesale channel sales grew 65% year-over-year to $1.8 million in Q2 FY2026. Includes sales to retail partners, health food stores, and other distributors. Bluebird Botanicals acquisition expanded wholesale capabilities.

stocktitan.net
3Clinical Healthcare Channel
TypeTransaction Fee
Description

New distribution channel launched April 2026 targeting physicians, health systems, and value-based care organizations following CMS Medicare BEI pathway activation. Allows eligible hemp-derived CBD products to be furnished to Medicare beneficiaries at up to $500 annually.

morningstar.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D, Infrastructure
Pricing details10 tiers
1Broad Spectrum CBD Gummies 30-count: $69.99 (one-time), $52.49 (Subscribe & Save)
ModelSubscriptionBilling cadenceMonthly
Notes

Available in 1500MG ($69.99), 3000MG ($84.99), 6000MG ($114.99) strengths. Subscribe & Save provides 25% discount.

cbdmd.com
2Full Spectrum CBD Gummies 30-count: $64.99 (one-time), $48.74 (Subscribe & Save)
ModelSubscriptionBilling cadenceMonthly
Notes

Available in 1500MG ($64.99), 3000MG, 6000MG strengths with tropical twist flavor.

cbdmd.com
3Broad Spectrum CBD Calming Gummies: $44.99 (one-time), $33.74 (Subscribe & Save)
ModelSubscriptionBilling cadenceMonthly
Notes

25MG CBD + 3MG CBG + 10MG CBN per gummy, 30-count, mixed berry flavor, THC-free.

cbdmd.com
4Full Spectrum CBD Calming Gummies: $84.99 (one-time), $63.74 (Subscribe & Save)
ModelSubscriptionBilling cadenceMonthly
Notes

100MG CBD + 5MG THC + 10MG CBN per gummy, 30-count, mixed berry flavor.

cbdmd.com
5Broad Spectrum CBD Sleep Gummies: $39.99 (one-time), $29.99 (Subscribe & Save)
ModelSubscriptionBilling cadenceMonthly
Notes

25MG CBD + 20MG CBN + 5MG melatonin per gummy, 30-count, tropical flavor, THC-free.

cbdmd.com
6Delta 9 THC Lights Out Sleep Gummies: $59.99 (one-time), $44.99 (Subscribe & Save)
ModelSubscriptionBilling cadenceMonthly
Notes

50MG CBD + 3MG THC + 20MG CBN per gummy, 30-count, slumberberry flavor.

cbdmd.com
7THCV + CBG Energy Softgels: $69.99 (one-time), $52.49 (Subscribe & Save)
ModelSubscriptionBilling cadenceMonthly
Notes

3MG THCV + 15MG CBG + 50MG caffeine + 500MCG B12 per softgel, 30-count.

cbdmd.com
8Broad Spectrum CBD Oil Tincture: Starting at $64.99 (one-time)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Available in Natural and Berry flavors, strengths from 750MG to 7500MG ($134.99).

cbdmd.com
9Delta 9 THC Gummies: $49.99 (one-time), $37.49 (Subscribe & Save)
ModelSubscriptionBilling cadenceMonthly
Notes

Available in 5MG and 10MG THC per serving, 20 or 30-count options.

cbdmd.com
10Herbal Oasis THC Beverages: $19.99 - $24.99 (4-pack)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Delta 9 THC Social Tonic available in 5MG and 10MG options with 4-pack, 12-pack, and 24-pack sizes.

cbdmd.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Bluebird Botanicals
Description

Acquired long-standing CBD brand with loyal consumer following, backed by private equity firm Juggernaut Capital Partners

prnewswire.com
+3 more records
Core offering1 text field

cbdMD manufactures and sells a diversified portfolio of hemp-derived CBD and Delta-9 THC wellness products across multiple delivery formats including gummies, tinctures, softgels, topicals, and beverages. The company operates as a multi-brand wellness platform spanning cannabinoid, pet, botanical, and functional health segments, with core brands including cbdMD, Bluebird Botanicals, Paw CBD, and Herbal Oasis. Primary revenue is generated through direct-to-consumer e-commerce subscriptions and one-time purchases of its Superior Broad Spectrum and Full Spectrum CBD formulations.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

cbdMD is a hemp-derived wellness company offering a diversified portfolio of CBD and THC products across multiple delivery formats. The company operates as a multi-brand wellness platform spanning cannabinoid, pet, botanical, and functional health segments, with core brands including cbdMD, Bluebird Botanicals, Paw CBD, and Oasis. Product offerings center on Superior Broad Spectrum CBD formulations (THC-free) and Full Spectrum CBD+THC products, available as gummies, tinctures, softgels, topicals, and beverages. The company also offers a clinical healthcare channel for Medicare-eligible hemp-derived CBD products.

Product and service1 record
1Broad Spectrum CBD Gummies
Scale indicator15 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest US-focused hemp-derived CBD wellness brand selling tinctures, gummies, topicals, and pet products via DTC, wholesale, and practitioner channels — the closest direct competitor to cbdMD across product mix, customer base, and distribution strategy.

TypeDirect peer
Description

Direct-to-consumer CBD brand with broad spectrum and full spectrum oils, gummies, capsules, and topicals — directly comparable pricing, assortment, and target consumer.

TypeDirect peer
Description

Pharmacist-founded CBD brand selling gummies, oils, topicals, and pet products via DTC and wholesale to retailers and pharmacies — directly comparable product catalog and channel mix to cbdMD.

TypeDirect peer
Description

Vertically integrated CBD brand selling tinctures, capsules, topicals, and pet products at value price points via DTC and wholesale — overlapping assortment and channel structure.

TypeDirect peer
Description

Public CBD specialty brand (OTC: CVSI) offering PlusCBD Oil gummies, capsules, topicals and pet products with a practitioner/retail channel mix that closely overlaps cbdMD's positioning.

TypeBroad incumbent
Description

Cannabis incumbent that acquired Lord Jones (CBD) and Spinach (edibles); broader cannabis exposure but overlapping cannabinoid edible and wellness positioning relevant to cbdMD's evolving THC beverage strategy.

TypeDirect peer
Description

CBD wellness brand focused on tinctures, topicals, sleep and calming gummies sold via DTC and retail; comparable formulation strategy and customer demographic.

TypeBroad incumbent
Description

Established supplement platform that has expanded into CBD and THC gummies via its 'Irwin' brand — broader portfolio but overlapping customer demographic in the wellness supplement category.

TypeDirect peer
Description

Long-standing independent CBD brand acquired by cbdMD in January 2026; its prior peer set (Hemp Bombs, Koi CBD, CBDistillery) competes directly with cbdMD's core broad-spectrum and full-spectrum SKUs.

TypeDirect peer
Description

Globally distributed hemp-derived CBD brand selling capsules, tinctures, topicals and pet products; comparable product formulation and regulatory positioning outside Australia.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

cbdMD

Hemp-Derived CBD Wellness Productscbdmd.com

cbdMD firmographics

Firmographics
Name
cbdMD
Legal name
cbdMD, Inc.
Website
https://cbdmd.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

cbdMD industry classification

Industry
Product category
Hemp-Derived CBD Wellness Products
NAICS
Food (Health) Supplement Retailers (456191), Tobacco, Electronic Cigarette, and Other Smoking Supplies Retailers (459991), Pharmacies and Drug Retailers (456110)
SIC
Retail-Drug Stores And Proprietary Stores (5912), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYCRANAHAC
CBD/Hemp Wellness & Supplements Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAD
Hemp-Derived Delta-8/Delta-9/THC-A Specialty Retail (Where Legal)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAF
CBD/Hemp Pet Products Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRANAHAB
CBD/Hemp Topicals & Beauty Retail
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)
SECONDARYCRAOAIAG
Hemp & CBD Product Wholesale Distribution
Consumer Products & Retail/Wholesale, Distribution & Category Management/Alcohol, Tobacco & Cannabis Wholesale Distribution

Keywords

  • CBD wellness products
  • Hemp-derived supplements
  • THC beverages
  • Pet CBD products
  • Broad spectrum CBD

Where cbdMD is headquartered

Location

Headquarters

HQ city
Charlotte
HQ country
United States
HQ region
North America

Offices1 record

Markets served

cbdMD business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

  1. Direct-to-Consumer E-commerce: Online sales through cbdmd.com website representing the majority of revenue (77% of FY2025 net sales at $14.7 million). Customers purchase various CBD products including gummies, tinctures, capsules, and topicals with Subscribe & Save subscription options offering 25% recurring discounts.
  2. Wholesale Distribution: Wholesale channel sales grew 65% year-over-year to $1.8 million in Q2 FY2026. Includes sales to retail partners, health food stores, and other distributors. Bluebird Botanicals acquisition expanded wholesale capabilities.
  3. Clinical Healthcare Channel: New distribution channel launched April 2026 targeting physicians, health systems, and value-based care organizations following CMS Medicare BEI pathway activation. Allows eligible hemp-derived CBD products to be furnished to Medicare beneficiaries at up to $500 annually.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyBroad Spectrum CBD Gummies 30-count: $69.99 (one-time), $52.49 (Subscribe & Save)
SubscriptionMonthlyFull Spectrum CBD Gummies 30-count: $64.99 (one-time), $48.74 (Subscribe & Save)
SubscriptionMonthlyBroad Spectrum CBD Calming Gummies: $44.99 (one-time), $33.74 (Subscribe & Save)
SubscriptionMonthlyFull Spectrum CBD Calming Gummies: $84.99 (one-time), $63.74 (Subscribe & Save)
SubscriptionMonthlyBroad Spectrum CBD Sleep Gummies: $39.99 (one-time), $29.99 (Subscribe & Save)
SubscriptionMonthlyDelta 9 THC Lights Out Sleep Gummies: $59.99 (one-time), $44.99 (Subscribe & Save)
SubscriptionMonthlyTHCV + CBG Energy Softgels: $69.99 (one-time), $52.49 (Subscribe & Save)
Unit PricingPay-as-you-goBroad Spectrum CBD Oil Tincture: Starting at $64.99 (one-time)
SubscriptionMonthlyDelta 9 THC Gummies: $49.99 (one-time), $37.49 (Subscribe & Save)
Unit PricingPay-as-you-goHerbal Oasis THC Beverages: $19.99 - $24.99 (4-pack)

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

cbdMD product offering

Product offering

Core offering

cbdMD manufactures and sells a diversified portfolio of hemp-derived CBD and Delta-9 THC wellness products across multiple delivery formats including gummies, tinctures, softgels, topicals, and beverages. The company operates as a multi-brand wellness platform spanning cannabinoid, pet, botanical, and functional health segments, with core brands including cbdMD, Bluebird Botanicals, Paw CBD, and Herbal Oasis. Primary revenue is generated through direct-to-consumer e-commerce subscriptions and one-time purchases of its Superior Broad Spectrum and Full Spectrum CBD formulations.

Product overview

cbdMD is a hemp-derived wellness company offering a diversified portfolio of CBD and THC products across multiple delivery formats. The company operates as a multi-brand wellness platform spanning cannabinoid, pet, botanical, and functional health segments, with core brands including cbdMD, Bluebird Botanicals, Paw CBD, and Oasis. Product offerings center on Superior Broad Spectrum CBD formulations (THC-free) and Full Spectrum CBD+THC products, available as gummies, tinctures, softgels, topicals, and beverages. The company also offers a clinical healthcare channel for Medicare-eligible hemp-derived CBD products.

Differentiator

Problem solved

Functional benefit

Brands

  • Bluebird Botanicals: Acquired long-standing CBD brand with loyal consumer following, backed by private equity firm Juggernaut Capital Partners
  • Paw CBD
  • Oasis
  • Herbal Oasis

Products and services

  • Broad Spectrum CBD Gummies

Companies that use cbdMD

Customer profile

Segments5 records

Ideal customer profiles5 records

cbdMD technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

cbdMD partnerships and signals

Strategic signal

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

cbdMD competitors and assessment

Company assessment

Direct peers

  • Charlotte's Web Holdings: Largest US-focused hemp-derived CBD wellness brand selling tinctures, gummies, topicals, and pet products via DTC, wholesale, and practitioner channels — the closest direct competitor to cbdMD across product mix, customer base, and distribution strategy.
  • CBDistillery: Direct-to-consumer CBD brand with broad spectrum and full spectrum oils, gummies, capsules, and topicals — directly comparable pricing, assortment, and target consumer.
  • Green Roads: Pharmacist-founded CBD brand selling gummies, oils, topicals, and pet products via DTC and wholesale to retailers and pharmacies — directly comparable product catalog and channel mix to cbdMD.
  • Lazarus Naturals: Vertically integrated CBD brand selling tinctures, capsules, topicals, and pet products at value price points via DTC and wholesale — overlapping assortment and channel structure.
  • CV Sciences (PlusCBD Oil): Public CBD specialty brand (OTC: CVSI) offering PlusCBD Oil gummies, capsules, topicals and pet products with a practitioner/retail channel mix that closely overlaps cbdMD's positioning.
  • Medterra: CBD wellness brand focused on tinctures, topicals, sleep and calming gummies sold via DTC and retail; comparable formulation strategy and customer demographic.
  • Bluebird Botanicals (pre-acquisition positioning): Long-standing independent CBD brand acquired by cbdMD in January 2026; its prior peer set (Hemp Bombs, Koi CBD, CBDistillery) competes directly with cbdMD's core broad-spectrum and full-spectrum SKUs.
  • Elixinol: Globally distributed hemp-derived CBD brand selling capsules, tinctures, topicals and pet products; comparable product formulation and regulatory positioning outside Australia.

Broad incumbents

  • Cronos Group: Cannabis incumbent that acquired Lord Jones (CBD) and Spinach (edibles); broader cannabis exposure but overlapping cannabinoid edible and wellness positioning relevant to cbdMD's evolving THC beverage strategy.
  • Irwin Naturals: Established supplement platform that has expanded into CBD and THC gummies via its 'Irwin' brand — broader portfolio but overlapping customer demographic in the wellness supplement category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

cbdMD social profiles

Digital presence

cbdMD compliance and trust

Trust signal

Compliance2 records

cbdMD financial estimates

Financial estimate

Revenue estimate

Valuation estimate

cbdMD leadership team

Management profile

Number of profiles

Profiles3 records

cbdMD subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

cbdMD funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

cbdMD M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about cbdMD

What does cbdMD do?

cbdMD manufactures and sells a diversified portfolio of hemp-derived CBD and Delta-9 THC wellness products across multiple delivery formats including gummies, tinctures, softgels, topicals, and beverages. The company operates as a multi-brand wellness platform spanning cannabinoid, pet, botanical, and functional health segments, with core brands including cbdMD, Bluebird Botanicals, Paw CBD, and Herbal Oasis. Primary revenue is generated through direct-to-consumer e-commerce subscriptions and one-time purchases of its Superior Broad Spectrum and Full Spectrum CBD formulations.

Is cbdMD a public or private company?

cbdMD is a public company. It is classified as public and is currently operating.

When was cbdMD founded?

cbdMD was founded in 2015. It employs 51 to 100 people.

Where is cbdMD based?

cbdMD is headquartered in Charlotte, United States, in the North America region.

How does cbdMD make money?

Three revenue lines are on record. Direct-to-Consumer E-commerce is the primary driver. The others are wholesale Distribution and clinical Healthcare Channel.

Who are cbdMD's main competitors?

Direct peers on record are Charlotte's Web Holdings, CBDistillery, Green Roads, Lazarus Naturals, CV Sciences (PlusCBD Oil), Medterra, Bluebird Botanicals (pre-acquisition positioning) and Elixinol. Broad incumbents are Cronos Group and Irwin Naturals.

Does cbdMD have an API?

No public API is recorded for cbdMD.

What industry is cbdMD in?

cbdMD's product category is Hemp-Derived CBD Wellness Products. Its primary akta.pro industry code is CRANAHAC, CBD/Hemp Wellness & Supplements Retail, with a secondary code of CRANAHAD, Hemp-Derived Delta-8/Delta-9/THC-A Specialty Retail (Where Legal). Its NAICS code is 456191 and its SIC code is 5912.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphacbdMD, Inc. (YCBD) Q3 2026 Earnings Call TranscriptcbdMD, Inc. held its Q3 2026 earnings call to discuss the financial results reported in its recent Form 10-Q filing. The event served as a standard procedural update for investors regarding the company's fiscal performance.PR NewswirecbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026cbdMD, Inc. reported a 20% year-over-year increase in third-quarter fiscal revenue to $5.6 million, driven by strong wholesale growth and the first full quarter of contribution from its acquired Bluebird Botanicals unit. Despite top-line gains, the company posted a net loss due to one-time M&A and legal costs, while implementing cost-reduction initiatives expected to save up to $150,000 monthly. The firm also highlighted expanding distribution for its Oasis beverage brand and favorable legislative momentum regarding federal hemp regulations.AInvestcbdMD: Revenue Turning, But The Stock Has Run Ahead of the ProofcbdMD (YCBD) is preparing to report Q3 FY2026 results on August 13, with its stock having risen 57% year-to-date as investors price in sequential revenue growth and the integration of Bluebird Botanicals. The company faces ongoing financial strain, evidenced by an $801K operating loss in Q2 and margin compression, while maintaining a thin cash runway that necessitates careful capital management.AInvestcbdMD's Q3 Preview: A 57% YTD Run, a $7.3 Million Market Cap, and a November CliffcbdMD is preparing to report Q3 fiscal 2026 results that will test the profitability of its January acquisition of Bluebird Botanicals amid ongoing cash burn and margin compression. The company faces a critical regulatory deadline on November 12, 2026, regarding hemp definitions, which industry groups estimate could impact 95% of the CBD market. Additionally, cbdMD is pursuing a long-term strategic bet on CMS Medicare reimbursement pathways, though revenue from this initiative is not expected for 12 to 18 months.YahoocbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter ResultscbdMD, Inc. will host a conference call on August 13, 2026, to discuss its financial results for the third quarter ending June 30, 2026. The call is part of the company's effort to communicate its business progress to stakeholders. cbdMD is recognized as a leading cannabidiol (CBD) brand in the U.S.Stock TitancbdMD Sets Aug. 13 Call for Q3 Financial ResultscbdMD, Inc. announced it will host a conference call on August 13, 2026, to discuss its third quarter financial results for the period ending June 30, 2026. The company focuses on CBD and related products, including THC-free CBD, Delta 9 products, and functional beverages.Investing.comSenate bill proposes delay of hemp product restrictions By Investing.comThe Senate Appropriations Committee released a continuing resolution text that would delay federal restrictions on hemp products from November 12 to December 11, 2026, giving Congress additional time to develop permanent regulatory framework. The bill still needs to pass the House, receive Senate approval, and obtain presidential signature before becoming law. cbdMD and the U.S. Hemp Roundtable have characterized the development as a significant positive for the hemp industry, with the CEO calling it a bridge measure.Third NewscbdMD Welcomes Senate Spending Bill Ensuring Access to CBD ProductsThe Senate Appropriations Committee released a continuing resolution on August 2 that would delay federal restrictions on hemp products until December 11, providing temporary protection for naturally derived full-spectrum CBD products. cbdMD, Inc., which produces hemp-derived CBD products, has welcomed the bill, with CEO T. Ronan Kennedy calling it 'a bridge, not the finish line' while noting this marks the first time protections for naturally derived hemp products have appeared in a base spending bill text. The legislation still requires passage by both the House and Senate and presidential signature to become law.YahoocbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp ProductscbdMD, Inc. welcomed Senate spending legislation released August 2 that would delay pending federal hemp restrictions from November 12 to December 11, potentially preserving access to full-spectrum CBD and naturally derived hemp products. The U.S. Hemp Roundtable called the provision a "landmark victory" and the biggest industry win since the 2018 Farm Bill. The company noted the text is not yet law and must pass both chambers and receive presidential signature before taking effect.Stock TitancbdMD Senate Bill Could Delay Hemp Rules to Dec. 11cbdMD, Inc. welcomed a Senate continuing resolution released August 2 that would delay pending federal hemp restrictions from November 12 to December 11, preserving access to full-spectrum CBD and naturally derived hemp products during the extension period. The bill includes a carve-out affecting synthetic cannabinoids on the original November 12 timeline while protecting naturally derived formulations that the company says fall within its core portfolio. The measure still requires retention through final House and Senate action and presidential signature before taking effect.